 
字體：小 中 大 |
|
|
|
| 2017/08/08 21:17:06瀏覽338｜回應0｜推薦1 | |
| ARNA昨天盤後公布本季財報，營利沒有預期的好，但我想這可能是個好機會，因為該公司的新產品ralinepag(治療hypertension病)已經通過食品管理局(FDA)第二期的測試，建議在$20.61或低購買，我給它的目標價為$49-50，另外，生化科技股是目前漲翻天的股市唯一還沒有漲太多的股類，銀髮族愈來愈需要新藥，生化科技股“錢”程萬里！祝您好運！
公司簡介：Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohns disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Companys drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Companys drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Companys programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s). 法律聲明：1.股票投資有風險，務必愼重評估 及 自負後果。 2.我目前持有以上股票。 |
|
| ( 知識學習｜商業管理 ) |
